Abiopharma

🔍 Binns Justin T (Executive)

Company: SHERWIN WILLIAMS CO (SHW)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 13,500 shares of Common Stock at $90.04 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,437.00 | transaction_form_type: 4
• Sold 13,500 shares of Common Stock at $352.7 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,937.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 813 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: G | equity_swap_involved: 0 | shares_owned_after: 21,124.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: 401(k) Plan | shares_owned_after: 6,009.63 | Footnotes: F3
• Sold 13,500 shares of Employee Stock Option (Right to Buy) at $90.04 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2026-10-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $352.66 per share. The Reporting Person undertakes to provide to The Sherwin-Williams Company, any security holder of The Sherwin-Williams Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: Represents a gift made by the Reporting Person to a charitable donor advised fund.
• F3: Represents the number of shares of Common Stock attributable to the Reporting Person's participation in The Sherwin-Williams Company 401(k) Plan per the trustee's 6/30/2026 statement.
• F4: These options were granted on October 18, 2016 and vested in three equal installments on each of the first three anniversaries of the date of grant, subject to vesting conditions.